Christopher Hulme

Christopher Hulme is a Professor in the Department of Pharmacology and Toxicology at the University of Arizona's College of Pharmacy. He is affiliated with the Skaggs Pharmaceutical Sciences Center and holds a B.S. (1989) and Ph.D. (1992) from Hertford College, University of Oxford. His postdoctoral training included roles at the University of Texas, Austin (1992-1994) and RPR (1994-1999), followed by industry experience at Amgen (1999-2004). His research focuses on chemical biology, small molecule drug design, and development of enabling synthetic methodologies, particularly targeting kinases for neurodegenerative and oncological therapies.

Key research interests include DYRK1A kinase inhibition for Alzheimer’s disease and viral entry modulation, PROTAC-based protein degradation, and multicomponent reactions for fluorescent and drug-like molecule synthesis. His work bridges academia and industry, emphasizing translational drug discovery. Over 50 peer-reviewed articles since 2012 highlight his contributions to kinase inhibitor design, proteolysis targeting chimera (PROTAC) development, and synthetic method innovation.

Notable achievements include discovery of DYR533 (a DYRK1A inhibitor reducing tau pathology in AD models) and DYR726 (a brain-penetrant PI3Kα inhibitor). His methodologies enable rapid synthesis of complex molecules via multicomponent reactions, advancing drug discovery efficiency. Active in collaborative research with pharmaceutical companies and academic institutions, he continues to innovate in small molecule therapeutics.